Abstract：
OBJECTIVE: 68Ga-Prostate-specific membrane antigen (PSMA) PET/CT is widely used in patients with biochemical recurrence (BCR) after radical prostatectomy. We collected data about patients staged with PSMA PET/CT after BCR (PSA < 1 ng/ml) in four different institutes. Impact of baseline features (Gleason score, risk classification, PSA at recurrence, PSA doubling time and time to recurrence) was explored to understand predictive factors of (PSMA) PET/CT positivity. Impact of restaging on following treatment approaches was reported.
RESULTS: 92 patients were included. PSMA PET/CT detection rate was 56.5% and low-volume disease (≤ 3 non-visceral lesions) was detected in 52.2% of patients. After positive scan, 13.5% of patients still lies on observation, ADT alone was administered in 30.8% of cases, Stereotactic body RT (SBRT) alone was delivered to 44.2% of patients and 11.5% of patients underwent concomitant SBRT and ADT. Seven patients underwent conventional salvage prostate bed RT. Chi-squared test showed a higher rate of positive PSMA PET/CT for patients with Gleason score > 7 (p = 0.004) and TTR < 29.5 months (p = 0.003).
CONCLUSIONS: PSMA PET/CT showed a high detection rate. This influenced clinical management in a significant percentage of patients, allowing treatment tailoring on the basis of imaging.
RESULTS: 92 patients were included. PSMA PET/CT detection rate was 56.5% and low-volume disease (≤ 3 non-visceral lesions) was detected in 52.2% of patients. After positive scan, 13.5% of patients still lies on observation, ADT alone was administered in 30.8% of cases, Stereotactic body RT (SBRT) alone was delivered to 44.2% of patients and 11.5% of patients underwent concomitant SBRT and ADT. Seven patients underwent conventional salvage prostate bed RT. Chi-squared test showed a higher rate of positive PSMA PET/CT for patients with Gleason score > 7 (p = 0.004) and TTR < 29.5 months (p = 0.003).
CONCLUSIONS: PSMA PET/CT showed a high detection rate. This influenced clinical management in a significant percentage of patients, allowing treatment tailoring on the basis of imaging.
摘要：
目的：68Ga-前列腺特异性膜抗原（PSMA）PET/CT广泛应用于前列腺癌根治术后生化复发（BCR）患者。我们收集了四个不同机构的BCR（PSA<1ng/ml）后PSMAPET/CT分期患者的数据。基线特征的影响(格里森评分，风险分类，复发时的PSA,探索PSA倍增时间和复发时间）以了解（PSMA）PET/CT阳性的预测因素。报道了重新分组对以下治疗方法的影响。
结果：92例患者被纳入。PSMAPET/CT检出率为56.5%,52.2%的患者检出小体积病变(≤3个非内脏病变)。阳性扫描后,13.5％的患者仍在观察中，在30.8％的病例中单独使用ADT，仅对44.2％的患者进行了立体定向放疗（SBRT），而11.5％的患者同时进行了SBRT和ADT。7例患者行常规抢救前列腺床RT。卡方检验显示，Gleason评分>7（p=0.004）和TTR<29.5个月（p=0.003）的患者PSMAPET/CT阳性率更高。
结论：PSMAPET/CT显示出较高的检出率。这影响了很大一部分患者的临床管理，允许在成像的基础上定制治疗。
结果：92例患者被纳入。PSMAPET/CT检出率为56.5%,52.2%的患者检出小体积病变(≤3个非内脏病变)。阳性扫描后,13.5％的患者仍在观察中，在30.8％的病例中单独使用ADT，仅对44.2％的患者进行了立体定向放疗（SBRT），而11.5％的患者同时进行了SBRT和ADT。7例患者行常规抢救前列腺床RT。卡方检验显示，Gleason评分>7（p=0.004）和TTR<29.5个月（p=0.003）的患者PSMAPET/CT阳性率更高。
结论：PSMAPET/CT显示出较高的检出率。这影响了很大一部分患者的临床管理，允许在成像的基础上定制治疗。
